SG Americas Securities LLC Sells 62,536 Shares of Cellebrite DI Ltd. $CLBT

SG Americas Securities LLC reduced its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 82.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,766 shares of the company’s stock after selling 62,536 shares during the period. SG Americas Securities LLC’s holdings in Cellebrite DI were worth $255,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Financial Management Professionals Inc. purchased a new position in Cellebrite DI during the third quarter worth about $28,000. CWM LLC boosted its position in shares of Cellebrite DI by 85.7% during the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Cellebrite DI by 68.3% during the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after purchasing an additional 819 shares in the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Cellebrite DI during the third quarter worth about $38,000. Finally, PNC Financial Services Group Inc. increased its position in shares of Cellebrite DI by 1,998.0% in the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after purchasing an additional 1,998 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Up 0.2%

NASDAQ CLBT opened at $16.59 on Wednesday. The firm has a market cap of $3.97 billion, a PE ratio of 53.52, a price-to-earnings-growth ratio of 2.31 and a beta of 1.28. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30. The stock has a 50-day moving average of $17.78 and a 200-day moving average of $17.01.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The company had revenue of $126.03 million during the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.Cellebrite DI’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same period last year, the firm earned $0.14 earnings per share. As a group, equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on CLBT. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Lake Street Capital lifted their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Needham & Company LLC upped their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.00.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.